Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

57.71 +10.92 (+23.34%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 26, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	7,063,564
Open	47.39
Bid (Size)	57.23 (100)
Ask (Size)	58.16 (100)
Prev. Close	46.79
Today's Range	45.09 - 59.15
52wk Range	9.570 - 46.92
Shares Outstanding	105,736,200
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Arrowhead Pharmaceuticals Stock Jumps 22% After Morgan Stanley Hikes Price Target ↗

Today 11:44 EST

Via Stocktwits

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Reports Strong Q4 2025 Revenue Beat and First FDA Approval ↗

November 25, 2025

Arrowhead Pharmaceuticals exceeded Q4 2025 revenue expectations, driven by its first FDA-approved drug and strong collaborations, marking its shift to a commercial-stage company.

Via Chartmill

Performance

YTD	+193.7%	+193.7%
1 Month	+46.2%	+46.2%
3 Month	+172.5%	+172.5%
6 Month	+275.5%	+275.5%
1 Year	+207.1%	+207.1%

More News

Arrowhead (ARWR) Q4 2025 Earnings Call Transcript ↗

November 25, 2025

Via The Motley Fool

Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results

November 25, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Stock Rockets 11% Today – Retail Says $200M Upfront Payment From Novartis Collaboration Is ‘Hell Of A Deal’ ↗

September 02, 2025

Via Stocktwits

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

November 24, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 19, 2025

Via Benzinga

FDA Clears Arrowhead Pharma's First-Ever Home Injection For Rare Fat Disorder ↗

November 18, 2025

Via Benzinga

Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

November 18, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial ↗

November 11, 2025

Via Benzinga

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results

November 06, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Privium Fund Management Sells Into Strength in Pharma Stock ↗

November 04, 2025

Via The Motley Fool

Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences

November 04, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

October 28, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis

October 21, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

October 07, 2025

From Arrowhead Pharmaceuticals

Via Business Wire

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals ↗

September 29, 2025

Via Benzinga

Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals

September 11, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

September 10, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Why Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal ↗

September 05, 2025

Via The Motley Fool

Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗

September 02, 2025

Via Benzinga

Arrowhead Pharma Jumps After Inking A Deal Worth Up To $2.2 Billion ↗

September 02, 2025

Via Investor's Business Daily

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement

September 02, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences

August 27, 2025

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

This Analyst Says Sarepta Lost Credibility By Exiting Arrowhead At A Loss, But Retail Sees Stock Hitting $30 By Next Week ↗

August 14, 2025

Via Stocktwits

Frequently Asked Questions

Is Arrowhead Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Arrowhead Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Arrowhead Pharmaceuticals, Inc. - Common Stock trade on?

Arrowhead Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Arrowhead Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Arrowhead Pharmaceuticals, Inc. - Common Stock is ARWR on the Nasdaq Stock Market

What is the current price of Arrowhead Pharmaceuticals, Inc. - Common Stock?

The current price of Arrowhead Pharmaceuticals, Inc. - Common Stock is 57.71

When was Arrowhead Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Arrowhead Pharmaceuticals, Inc. - Common Stock was at 11/26/25 04:00 PM ET

What is the market capitalization of Arrowhead Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Arrowhead Pharmaceuticals, Inc. - Common Stock is 6.10B

How many shares of Arrowhead Pharmaceuticals, Inc. - Common Stock are outstanding?

Arrowhead Pharmaceuticals, Inc. - Common Stock has 6B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.